Insights into the future of first-line advanced hepatocellular carcinoma treatment
Atezolizumab plus bevacizumab is the standard of care for patients with advanced hepatocellular carcinoma. Building on the impressive results of IMBrave150,1 the phase 1b–2 MORPHEUS-Liver trial2 compared another dual immune checkpoint inhibitor regimen, the combination of atezolizumab plus bevacizumab with the first-in-class anti-TIGIT antibody tiragolumab, with atezolizumab plus bevacizumab alone. Tiragolumab could improve on the efficacy of atezolizumab plus bevacizumab through its diverse effects on CD8+ T cells, regulatory T cells, and tumour-associated macrophages.
